Niacin: an old lipid drug in a new NAD+ dress
Niacin, the first antidyslipidemic drug, has been at the center stage of lipid research for many decades before the discovery of statins. However, to date, despite its remarkable effects on lipid profiles, the clinical outcomes of niacin treatment on cardiac events is still debated. In addition to i...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2019-04-01
|
| Edice: | Journal of Lipid Research |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S0022227520325864 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|